Loading...
XSHE
300497
Market cap1.51bUSD
Jul 10, Last price  
18.32CNY
1D
-3.38%
1Q
-0.60%
Jan 2017
20.65%
IPO
334.43%
Name

Jiangxi Fushine Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300497 chart
P/E
P/S
8.35
EPS
Div Yield, %
Shrs. gr., 5y
-0.44%
Rev. gr., 5y
-3.73%
Revenues
1.18b
+0.35%
291,367,461360,320,580442,842,086510,727,122579,743,064763,686,934958,150,4751,163,433,5901,354,046,8111,492,952,9901,429,542,8741,429,542,8741,647,263,4261,647,263,4251,609,669,9871,177,846,6011,181,911,663
Net income
0k
P
35,847,26840,079,43245,072,69153,441,24893,601,772173,909,449177,550,397194,724,802305,835,266319,300,20648,830,66248,830,6700-141,471,319-200,800,045-272,100,5450
CFO
63m
-66.60%
33,797,85463,195,80557,219,00031,389,54774,008,650188,534,194210,723,307175,913,935337,910,973382,350,65172,321,5560-64,762,951187,639,94362,673,556
Dividend
Jul 08, 20210.2 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Jiangxi Fushine Pharmaceutical Co., Ltd. is engaged in the global research, development, production, and marketing of active pharmaceutical ingredients (APIs) and key chemical compounds for drug synthesis. Its product portfolio includes important antibiotics like penicillin and carbapenem, alongside a variety of other pharmaceutical offerings. The company also extends its expertise by providing contract research, development, and manufacturing services. Founded in 2002 and headquartered in Jingdezhen, China, the firm was initially named Jingdezhen Fuxiang Pharmaceutical Co., Ltd. before adopting its current designation in August 2012.
IPO date
Dec 22, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT